Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Study:

Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma

Rationale:

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory stage II or stage III multiple myeloma.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm Drug: arsenic trioxide Phase 2

Verified by Cell Therapeutics June, 2002

Sponsored by: Cell Therapeutics
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00017433

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Carolyn Paradise, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site